EDIT Quote, Financials, Valuation and Earnings

Arcutis Biotherapeutics, Inc. has a net margin of -332.98% compared to Editas Medicine, Inc.'s net margin of 7.47%. Editas Medicine, Inc.'s return on equity of -246.73% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

Editas Medicine, Inc. has a consensus price target of $5.13, signalling upside risk potential of 147.59%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 12.07%. Given that Editas Medicine, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Editas Medicine, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

Editas Medicine, Inc. has a beta of 2.164, which suggesting that the stock is 116.414% more volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.710, suggesting its more volatile than the S&P 500 by 70.962%.

Editas Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Editas Medicine, Inc. quarterly revenues are $7.5M, which are smaller than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Editas Medicine, Inc.'s net income of -$25.1M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Editas Medicine, Inc.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine, Inc. is 3.80x versus 11.34x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cogent Biosciences, Inc. has a net margin of -332.98% compared to Editas Medicine, Inc.'s net margin of --. Editas Medicine, Inc.'s return on equity of -246.73% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Editas Medicine, Inc. has a consensus price target of $5.13, signalling upside risk potential of 147.59%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $50.25 which suggests that it could grow by 42.15%. Given that Editas Medicine, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Editas Medicine, Inc. is more attractive than Cogent Biosciences, Inc..

Editas Medicine, Inc. has a beta of 2.164, which suggesting that the stock is 116.414% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.585%.

Editas Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Editas Medicine, Inc. quarterly revenues are $7.5M, which are larger than Cogent Biosciences, Inc. quarterly revenues of --. Editas Medicine, Inc.'s net income of -$25.1M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Editas Medicine, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine, Inc. is 3.80x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Daré Bioscience, Inc. has a net margin of -332.98% compared to Editas Medicine, Inc.'s net margin of -154904.35%. Editas Medicine, Inc.'s return on equity of -246.73% beat Daré Bioscience, Inc.'s return on equity of --.

Editas Medicine, Inc. has a consensus price target of $5.13, signalling upside risk potential of 147.59%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 442.93%. Given that Daré Bioscience, Inc. has higher upside potential than Editas Medicine, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Editas Medicine, Inc..

Editas Medicine, Inc. has a beta of 2.164, which suggesting that the stock is 116.414% more volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.454%.

Editas Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.

Editas Medicine, Inc. quarterly revenues are $7.5M, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Editas Medicine, Inc.'s net income of -$25.1M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Editas Medicine, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine, Inc. is 3.80x versus 399.70x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics, Inc. has a net margin of -332.98% compared to Editas Medicine, Inc.'s net margin of -243.13%. Editas Medicine, Inc.'s return on equity of -246.73% beat Janux Therapeutics, Inc.'s return on equity of -10.94%.

Editas Medicine, Inc. has a consensus price target of $5.13, signalling upside risk potential of 147.59%. On the other hand Janux Therapeutics, Inc. has an analysts' consensus of $64.29 which suggests that it could grow by 354.06%. Given that Janux Therapeutics, Inc. has higher upside potential than Editas Medicine, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Editas Medicine, Inc..

Editas Medicine, Inc. has a beta of 2.164, which suggesting that the stock is 116.414% more volatile than S&P 500. In comparison Janux Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Editas Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine, Inc. pays -- of its earnings as a dividend. Janux Therapeutics, Inc. pays out -- of its earnings as a dividend.

Editas Medicine, Inc. quarterly revenues are $7.5M, which are smaller than Janux Therapeutics, Inc. quarterly revenues of $10M. Editas Medicine, Inc.'s net income of -$25.1M is lower than Janux Therapeutics, Inc.'s net income of -$24.3M. Notably, Editas Medicine, Inc.'s price-to-earnings ratio is -- while Janux Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine, Inc. is 3.80x versus 85.86x for Janux Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.